Published in Curr Opin Cardiol on November 01, 2005
Hypercholesterolemia and microvascular dysfunction: interventional strategies. J Inflamm (Lond) (2010) 1.06
Effect of prior medical treatments on ischemic stroke severity and outcome. Funct Neurol (2011) 0.89
Influence of statin treatment on coronary atherosclerosis visualised using multidetector computed tomography. Eur Radiol (2010) 0.88
Effect of atorvastatin in patients with chronic heart failure - insights from randomized clinical trials. Arch Med Sci (2010) 0.88
Pathways of cholesterol homeostasis in mouse retina responsive to dietary and pharmacologic treatments. J Lipid Res (2014) 0.85
Statins for the prevention of stroke: a meta-analysis of randomized controlled trials. PLoS One (2014) 0.82
Effect of different loading doses of atorvastatin on percutaneous coronary intervention for acute coronary syndromes. Can J Cardiol (2010) 0.80
Impact of statins and beta-blocker therapy on mortality after coronary artery bypass graft surgery. Cardiovasc Diagn Ther (2015) 0.80
Clinical factors associated with statins prescription in acute ischemic stroke patients: findings from the Lombardia Stroke Registry. BMC Neurol (2014) 0.79
Long-term administration of rosuvastatin prevents contractile and electrical remodelling of diabetic rat heart. J Bioenerg Biomembr (2013) 0.78
Restenosis after renal artery angioplasty and stenting: incidence and risk factors. J Vasc Surg (2009) 0.78
Coronary risk assessment and management options in chronic kidney disease patients prior to kidney transplantation. Curr Cardiol Rev (2009) 0.77
Simvastatin inhibits sphingosylphosphorylcholine-induced differentiation of human mesenchymal stem cells into smooth muscle cells. Exp Mol Med (2012) 0.76
Pitavastatin suppresses mitogen activated protein kinase-mediated Erg-1 induction in human vascular smooth muscle cells. Eur J Pharmacol (2009) 0.76
The effects of pravastatin on the normal human placenta: Lessons from ex-vivo models. PLoS One (2017) 0.75
Effect of lipid-modifying therapy on long-term mortality after abdominal aortic aneurysm repair: a systemic review and meta-analysis. World J Surg (2015) 0.75
SUMO-specific protease 1 is essential for stabilization of HIF1alpha during hypoxia. Cell (2007) 4.46
Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med (2012) 3.20
SUMO-specific protease 2 is essential for suppression of polycomb group protein-mediated gene silencing during embryonic development. Mol Cell (2010) 2.52
Inflammatory cytokines stimulated C-reactive protein production by human coronary artery smooth muscle cells. Circulation (2003) 2.28
Characterization of a family of nucleolar SUMO-specific proteases with preference for SUMO-2 or SUMO-3. J Biol Chem (2006) 2.15
Role of desumoylation in the development of prostate cancer. Neoplasia (2006) 1.90
SENP1 enhances androgen receptor-dependent transcription through desumoylation of histone deacetylase 1. Mol Cell Biol (2004) 1.89
Radiation-related heart disease: current knowledge and future prospects. Int J Radiat Oncol Biol Phys (2010) 1.72
A proline-90 residue unique to SUMO-4 prevents maturation and sumoylation. Biochem Biophys Res Commun (2005) 1.68
Release of C-reactive protein in response to inflammatory cytokines by human adipocytes: linking obesity to vascular inflammation. J Am Coll Cardiol (2005) 1.67
Neddylation of a breast cancer-associated protein recruits a class III histone deacetylase that represses NFkappaB-dependent transcription. Nat Cell Biol (2006) 1.62
Resistin promotes smooth muscle cell proliferation through activation of extracellular signal-regulated kinase 1/2 and phosphatidylinositol 3-kinase pathways. Circulation (2004) 1.55
Regulation of DNA repair through deSUMOylation and SUMOylation of replication protein A complex. Mol Cell (2010) 1.50
Both cell fusion and transdifferentiation account for the transformation of human peripheral blood CD34-positive cells into cardiomyocytes in vivo. Circulation (2004) 1.46
SUMO Losing Balance: SUMO Proteases Disrupt SUMO Homeostasis to Facilitate Cancer Development and Progression. Genes Cancer (2010) 1.42
SENP3 is responsible for HIF-1 transactivation under mild oxidative stress via p300 de-SUMOylation. EMBO J (2009) 1.41
Induction of the SUMO-specific protease 1 transcription by the androgen receptor in prostate cancer cells. J Biol Chem (2007) 1.41
Nucleocytoplasmic shuttling modulates activity and ubiquitination-dependent turnover of SUMO-specific protease 2. Mol Cell Biol (2006) 1.29
SENP1 induces prostatic intraepithelial neoplasia through multiple mechanisms. J Biol Chem (2010) 1.29
Differential regulation of c-Jun-dependent transcription by SUMO-specific proteases. J Biol Chem (2005) 1.28
Emerging paradigms in cardiomyopathies associated with cancer therapies. Circ Res (2013) 1.27
Intra-abdominal adiposity, inflammation, and cardiovascular risk: new insight into global cardiometabolic risk. Curr Hypertens Rep (2008) 1.27
Kaposi's sarcoma-associated herpesvirus K-bZIP represses gene transcription via SUMO modification. J Virol (2005) 1.26
Human CD34+ cells in experimental myocardial infarction: long-term survival, sustained functional improvement, and mechanism of action. Circ Res (2010) 1.26
Vascular complications of selected cancer therapies. Nat Clin Pract Cardiovasc Med (2008) 1.24
Heat shock and Cd2+ exposure regulate PML and Daxx release from ND10 by independent mechanisms that modify the induction of heat-shock proteins 70 and 25 differently. J Cell Sci (2003) 1.20
SENP3-mediated de-conjugation of SUMO2/3 from promyelocytic leukemia is correlated with accelerated cell proliferation under mild oxidative stress. J Biol Chem (2010) 1.16
Regulation of the NEDD8 conjugation system by a splicing variant, NUB1L. J Biol Chem (2003) 1.15
Isocitrate-to-SENP1 signaling amplifies insulin secretion and rescues dysfunctional β cells. J Clin Invest (2015) 1.12
SUMO-specific protease 1 is critical for early lymphoid development through regulation of STAT5 activation. Mol Cell (2012) 1.11
Redox regulation of the stability of the SUMO protease SENP3 via interactions with CHIP and Hsp90. EMBO J (2010) 1.11
NF-κB induction of the SUMO protease SENP2: A negative feedback loop to attenuate cell survival response to genotoxic stress. Mol Cell (2011) 1.09
Fusion of human hematopoietic progenitor cells and murine cardiomyocytes is mediated by alpha 4 beta 1 integrin/vascular cell adhesion molecule-1 interaction. Circ Res (2007) 1.09
Therapy insight: Management of cardiovascular disease in patients with cancer and cardiac complications of cancer therapy. Nat Clin Pract Oncol (2008) 1.08
CRP and the risk of atherosclerotic events. Semin Immunopathol (2009) 1.06
Induction of SENP1 in endothelial cells contributes to hypoxia-driven VEGF expression and angiogenesis. J Biol Chem (2010) 1.06
Differential expression of SUMO-specific protease 7 variants regulates epithelial-mesenchymal transition. Proc Natl Acad Sci U S A (2012) 1.05
SUMOylation and de-SUMOylation in response to DNA damage. FEBS Lett (2011) 1.03
C-reactive protein: structure affects function. Circulation (2004) 1.00
De-SUMOylation enzyme of sentrin/SUMO-specific protease 2 regulates disturbed flow-induced SUMOylation of ERK5 and p53 that leads to endothelial dysfunction and atherosclerosis. Circ Res (2013) 0.99
C-reactive protein and atherothrombosis--beyond a biomarker: an actual partaker of lesion formation. Am J Physiol Regul Integr Comp Physiol (2003) 0.95
The diagnosis and management of cardiovascular disease in cancer patients. Curr Probl Cardiol (2008) 0.89
A new perspective on the biology of C-reactive protein. Circ Res (2005) 0.87
Molecular imaging of mesenchymal stem cell: mechanistic insight into cardiac repair after experimental myocardial infarction. Circ Cardiovasc Imaging (2011) 0.86
Inhibition of tumor-necrosis-factor-alpha induced endothelial cell activation by a new class of PPAR-gamma agonists. An in vitro study showing receptor-independent effects. J Vasc Res (2005) 0.84
Dual targeting of tumor angiogenesis and chemotherapy by endostatin-cytosine deaminase-uracil phosphoribosyltransferase. Mol Cancer Ther (2011) 0.84
PROCLAIM: pilot study to examine the effects of clopidogrel on inflammatory markers in patients with metabolic syndrome receiving low-dose aspirin. Tex Heart Inst J (2009) 0.84
SUMO-specific protease 1 regulates mitochondrial biogenesis through PGC-1α. J Biol Chem (2012) 0.83
Disturbed flow-activated p90RSK kinase accelerates atherosclerosis by inhibiting SENP2 function. J Clin Invest (2015) 0.83
Role of C-reactive protein in acute myocardial infarction and stroke: possible therapeutic approaches. Curr Pharm Biotechnol (2012) 0.82
The in vivo functions of desumoylating enzymes. Subcell Biochem (2010) 0.81
NUB1-mediated targeting of the ubiquitin precursor UbC1 for its C-terminal hydrolysis. Eur J Biochem (2004) 0.81
Weighing in on heart failure: the role of SERCA2a SUMOylation. Circ Res (2012) 0.81
An essential role of small ubiquitin-like modifier (SUMO)-specific Protease 2 in myostatin expression and myogenesis. J Biol Chem (2013) 0.80
Ubiquitin, proteasome, and restenosis: a brave new world for cardiovascular research. Circulation (2002) 0.79
Wrestling with heart failure: SUMO-1 to the rescue. Circ Res (2014) 0.79
Fusion of the SUMO/Sentrin-specific protease 1 gene SENP1 and the embryonic polarity-related mesoderm development gene MESDC2 in a patient with an infantile teratoma and a constitutional t(12;15)(q13;q25). Hum Mol Genet (2005) 0.78
Multitasking of the 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor: beyond cardiovascular diseases. Curr Atheroscler Rep (2004) 0.76
A proatherogenic role for C-reactive protein in vivo. Curr Opin Lipidol (2005) 0.76
Balancing act during development: lessons from a SUMO-less SF-1. Dev Cell (2011) 0.75
Cardiovascular risk associated with androgen deprivation therapy. Oncology (Williston Park) (2010) 0.75
Heparin and bone marrow-derived cell therapy: friend or foe? Circ Res (2012) 0.75
Cytokine profile and ST-elevation myocardial infarction. Circ Res (2012) 0.75
Microphthalmia-associated transcription factor, melanoma, and renal carcinoma: the small ubiquitin-like modifier connection. Pigment Cell Melanoma Res (2011) 0.75
Blood-derived progenitor cells after recanalization of chronic coronary artery occlusions in humans. Circ Res (2005) 0.75